Research graph
References from Targeting the BIR Domains of Inhibitor of Apoptosis (IAP) Proteins in Cancer Treatment. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/j.cell.2011.02.013
10.1016/j.cell.2011.02.013 · External reference
10.1128/jvi.67.4.2168-2174.1993
10.1128/jvi.67.4.2168-2174.1993 · External reference
10.1128/jvi.68.4.2521-2528.1994
10.1128/jvi.68.4.2521-2528.1994 · External reference
10.1016/0092-8674(95)90149-3
10.1016/0092-8674(95)90149-3 · External reference
10.1002/j.1460-2075.1996.tb00629.x
10.1002/j.1460-2075.1996.tb00629.x · External reference
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias
2000 · External reference
Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia
10.3324/haematol.10675 · 2007 · External reference
IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer
2010 · External reference
XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL
2010 · External reference
Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer
2011 · External reference
Nuclear cIAP1 overexpression is a tumor stage- and grade-independent predictor of poor prognosis in human bladder cancer patients
2012 · External reference
XIAP is a predictor of cisplatin-based chemotherapy response and prognosis for patients with advanced head and neck cancer
10.1371/journal.pone.0031601 · 2012 · External reference
Study of survivin and X-linked inhibitor of apoptosis protein (XIAP) genes in acute myeloid leukemia (AML)
2012 · External reference
Interaction of the baculovirus anti-apoptotic protein p35 with caspases. Specificity, kinetics, and characterization of the caspase/p35 complex
10.1021/bi980893w · 1998 · External reference
ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein. Mol.Cell
1997 · External reference
10.1074/jbc.273.14.7787
10.1074/jbc.273.14.7787 · External reference
10.1093/emboj/17.8.2215
10.1093/emboj/17.8.2215 · External reference
10.1074/jbc.m910231199
10.1074/jbc.m910231199 · External reference
Unresolved reference
2001 · External reference
10.1038/35065125
10.1038/35065125 · External reference
10.1016/s0092-8674(01)00274-4
10.1016/s0092-8674(01)00274-4 · External reference
Inhibitor of apoptosis (IAP) proteins in regulation of inflammation and innate immunity
2011 · External reference
10.1038/sj.embor.7400795
10.1038/sj.embor.7400795 · External reference
X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy
2014 · External reference
10.1016/j.bmc.2009.07.009
10.1016/j.bmc.2009.07.009 · External reference
10.1016/j.bbrc.2008.10.139
10.1016/j.bbrc.2008.10.139 · External reference
10.1016/j.ab.2007.10.032
10.1016/j.ab.2007.10.032 · External reference
10.1021/jm8006849
10.1021/jm8006849 · External reference
10.1016/j.jmb.2008.09.064
10.1016/j.jmb.2008.09.064 · External reference
Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP
10.1021/ja074725f · 2007 · External reference
10.1158/1078-0432.ccr-06-0608
10.1158/1078-0432.ccr-06-0608 · External reference
Randomized phase II study of the X-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)
2016 · External reference
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia
10.1200/jco.2009.21.8172 · 2009 · External reference
Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma
10.1097/coc.0b013e3182467a13 · 2013 · External reference
Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study
10.1016/j.clml.2011.03.033 · 2011 · External reference
10.1016/s1535-6108(03)00332-5
10.1016/s1535-6108(03)00332-5 · External reference
10.1021/jm030420
10.1021/jm030420 · External reference
10.1158/1078-0432.ccr-15-0365
10.1158/1078-0432.ccr-15-0365 · External reference
Unresolved reference
2000 · External reference
10.1038/35050006
10.1038/35050006 · External reference
10.1038/35050012
10.1038/35050012 · External reference
The activator of apoptosis Smac-DIABLO acts as a tetramer in solution
10.1016/j.bpj.2014.11.3471 · 2015 · External reference
10.1074/jbc.m401253200
10.1074/jbc.m401253200 · External reference
10.1038/nm735
10.1038/nm735 · External reference
10.1074/jbc.m207578200
10.1074/jbc.m207578200 · External reference
10.1016/j.ab.2004.05.055
10.1016/j.ab.2004.05.055 · External reference
10.1126/science.1098231
10.1126/science.1098231 · External reference
Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization. Bioorg.Med
2012 · External reference
10.1007/s10637-010-9475-6
10.1007/s10637-010-9475-6 · External reference
Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-kappaB-dependent manner
10.1038/onc.2012.108 · 2013 · External reference
Therapy of Smac mimetic SM-164 in combination with gemcitabine for pancreatic cancer
10.1016/j.canlet.2012.10.039 · 2013 · External reference
10.1038/sj.onc.1207967
10.1038/sj.onc.1207967 · External reference
10.1158/1541-7786.mcr-05-0231
10.1158/1541-7786.mcr-05-0231 · External reference
Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo
10.1158/0008-5472.can-08-1296 · 2008 · External reference
10.1158/0008-5472.can-08-2436
10.1158/0008-5472.can-08-2436 · External reference
Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib
2010 · External reference
10.1038/cddis.2013.67
10.1038/cddis.2013.67 · External reference
Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-alpha-independent mechanism
10.1007/s10549-012-2352-6 · 2013 · External reference
10.1016/j.ccr.2007.08.029
10.1016/j.ccr.2007.08.029 · External reference
10.1016/j.cell.2007.10.037
10.1016/j.cell.2007.10.037 · External reference
10.1016/j.cell.2007.10.030
10.1016/j.cell.2007.10.030 · External reference
10.1038/cdd.2011.10
10.1038/cdd.2011.10 · External reference
SMAC-mimetics activate the E3 ligase activity of cIAP1 by promoting RING dimerisation
2011 · External reference
Cellular inhibitors of apoptosis are global regulators of NF-kappaB and MAPK activation by members of the TNF family of receptors
2012 · External reference
10.1038/cddis.2013.70
10.1038/cddis.2013.70 · External reference
10.1038/416345a
10.1038/416345a · External reference
10.1038/s41418-018-0100-0
10.1038/s41418-018-0100-0 · External reference
10.1016/j.immuni.2009.04.011
10.1016/j.immuni.2009.04.011 · External reference
10.1016/j.semcdb.2014.03.035
10.1016/j.semcdb.2014.03.035 · External reference
10.1038/nri3325
10.1038/nri3325 · External reference
10.1111/j.1600-065x.2011.01066.x
10.1111/j.1600-065x.2011.01066.x · External reference
10.1038/nature09816
10.1038/nature09816 · External reference
Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
2017 · External reference
10.1038/nm.4229
10.1038/nm.4229 · External reference
10.1038/nbt.2806
10.1038/nbt.2806 · External reference
Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity
2013 · External reference
10.1182/blood-2013-06-510743
10.1182/blood-2013-06-510743 · External reference
Current status of immunotherapy for non-small-cell lung cancer
10.5301/tj.5000537 · 2016 · External reference
10.12688/f1000research.10625.1
10.12688/f1000research.10625.1 · External reference
10.1371/journal.pone.0021556
10.1371/journal.pone.0021556 · External reference
10.1073/pnas.1005667107
10.1073/pnas.1005667107 · External reference
10.1007/s10495-017-1375-1
10.1007/s10495-017-1375-1 · External reference
10.1038/cddis.2013.305
10.1038/cddis.2013.305 · External reference
10.15252/embj.201592060
10.15252/embj.201592060 · External reference
10.1038/bjc.2014.521
10.1038/bjc.2014.521 · External reference
10.1158/1078-0432.ccr-16-2172
10.1158/1078-0432.ccr-16-2172 · External reference
10.1158/0008-5472.can-07-5173
10.1158/0008-5472.can-07-5173 · External reference
10.1093/nar/gkg161
10.1093/nar/gkg161 · External reference
10.1111/febs.14616
10.1111/febs.14616 · External reference
10.1021/cb900083m
10.1021/cb900083m · External reference
Expedient synthesis of highly potent antagonists of inhibitor of apoptosis proteins (IAPs) with unique selectivity for ML-IAP
2013 · External reference
The inhibitor of apoptosis protein Livin (ML-IAP) plays a dual role in tumorigenicity
10.1158/0008-5472.can-09-0424 · 2009 · External reference
Characterization of a heterodimeric Smac-based peptide that features sequences specific to both the BIR2 and BIR3 domains of the X-linked inhibitor of apoptosis protein
10.1002/bip.21732 · 2012 · External reference
Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling
10.15252/embj.201899372 · 2018 · External reference
Design, synthesis and evaluation of monovalent Smac mimetics that bind to the BIR2 domain of the anti-apoptotic protein XIAP
2011 · External reference
Benzazepinones and benzoxazepinones as antagonists of inhibitor of apoptosis proteins (IAPs) selective for the second baculovirus IAP repeat (BIR2) domain
2013 · External reference
10.1021/jm400732v
10.1021/jm400732v · External reference
Disruption of XIAP-RIP2 Association Blocks NOD2-Mediated Inflammatory Signaling
2018 · External reference
10.1038/onc.2008.302
10.1038/onc.2008.302 · External reference
XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1 dimerization
2007 · External reference
Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation
2010 · External reference
NF023 binding to XIAP-BIR1: searching drugs for regulation of the NF-kappaB pathway
10.1002/prot.24766 · 2015 · External reference
Design of small-molecule peptidic and nonpeptidic Smac mimetics
2008 · External reference
Tumor necrosis factor: an apoptosis JuNKie?
10.1016/s0092-8674(04)00166-7 · 2004 · External reference
10.1021/jm500176w
10.1021/jm500176w · External reference
4-Connected azabicyclo[5.3.0]decane Smac mimetics-Zn(2+) chelators as dual action antitumoral agents
2017 · External reference
Synthesis and biological evaluation of dual action cyclo-RGD/SMAC mimetic conjugates targeting alpha(v)beta(3)/alpha(v)beta(5) integrins and IAP proteins
2014 · External reference
SPION-Smac mimetic nano-conjugates: putative pro-apoptotic agents in oncology
2014 · External reference
Proteolysis targeting chimera (PROTAC): a paradigm-shifting approach in small molecule drug discovery
2018 · External reference
Discovery of small molecules that induce the degradation of huntingtin
2017 · External reference
Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands
2017 · External reference
Development of a peptide-based inducer of nuclear receptors degradation
2016 · External reference
Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist
2012 · External reference
Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation
2013 · External reference
10.1128/mcb.21.10.3604-3608.2001
10.1128/mcb.21.10.3604-3608.2001 · External reference
10.1128/mcb.25.8.3348-3356.2005
10.1128/mcb.25.8.3348-3356.2005 · External reference
10.1128/mcb.26.2.699-708.2006
10.1128/mcb.26.2.699-708.2006 · External reference
10.1038/emboj.2012.18
10.1038/emboj.2012.18 · External reference
Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor alpha-induced necroptosis
10.1593/neo.11610 · 2011 · External reference
cIAPs block ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms
2011 · External reference
10.1038/cdd.2012.59
10.1038/cdd.2012.59 · External reference
10.1093/nar/gku316
10.1093/nar/gku316 · External reference
10.1002/pro.523
10.1002/pro.523 · External reference
